Generation of induced pluripotent stem cell line, ICGi007-A, by reprogramming peripheral blood mononuclear cells from a patient with Huntington's disease

• Published in: Stem cell research Vol. 34; p. 101382
• Main Authors: Grigor'eva, E.V., Malankhanova, T.B., Surumbayeva, A., Minina, J.M., Morozov, V.V., Abramycheva, N. Yu, Illarioshkin, S.N., Malakhova, A.A., Zakian, S.M.
• Format: Journal Article
• Language: English
• Published: England Elsevier B.V 01.01.2019; Elsevier
• ISSN: 1873-5061; 1876-7753
• DOI: 10.1016/j.scr.2018.101382

Huntington's disease (HD) is an autosomal dominant neurodegenerative disease caused by mutation in the HTT gene encoding HTT protein. The mutant protein leads to the neuronal death through dysregulation of multiple cellular processes. HD human induced pluripotent stem cells (iPSCs) represent a useful and valid model for the disease study. iPSC line from HD patient with 47 CAG repeats in HTT was generated from blood mononuclear cells by non-integrating episomal vectors. The iPSC line retained the mutation, expressed pluripotency markers, had a normal karyotype and displayed in vitro differentiation to the three germ layers. Resource table.Unlabelled TableUnique stem cell lines identifierICGi007-AAlternative name(s) of stem cell line47Q-3LfInstitutionFederal Research Center Institute of Cytology and Genetics, the Siberian Branch of the Russian Academy of Sciences, Novosibirsk, RussiaContact information of distributorElena V. Grigor'evaevlena@bionet.nsc.ruType of cell linesiPSCOriginHumanAdditional origin infoAge: 27Sex: FEthnicity: CaucasianCell SourcePeripheral blood mononuclear cellsClonalityClonalMethod of reprogrammingTransgene free episomal plasmid vectorsGenetic ModificationYESType of ModificationHereditaryAssociated diseaseHuntington's diseaseGene/locusHTT/4p16.3Method of modificationN/AName of transgene or resistanceN/AInducible/constitutive systemN/ADate archived/stock dateDecember 2017Cell line repository/bankhttps://hpscreg.eu/cell-line/ICGi007-AEthical approvalThe generation of iPSC line from cells donated by patient with informed consent was reviewed and approved by “Center of New Medical Technology in Akademgorodok” (protocol No. 21)